NCT07360405Recruiting
Dietary Intervention for Migraine Relief
Diet-Based Treatment for Migraine Relief
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress. The main questions this study aims to answer are: Does following a low-glutamate diet reduce the number of migraine days and the severity and duration of migraine attacks, and improve quality of life? Are improvements in migraine symptoms associated with changes in blood-based biological markers related to migraine activity? Researchers will compare participants assigned to the low-glutamate diet with participants assigned to a wait-list control group to evaluate differences in migraine outcomes and related biological measures. Participants will: Complete a baseline run-in period while tracking headaches using a daily migraine diary Either follow a low-glutamate dietary intervention or continue their usual diet as part of a wait-list control Complete standardized questionnaires related to migraine symptoms and quality of life Provide blood samples for laboratory analyses Undergo neuroimaging assessments (for a subset of participants)
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 19 Dec 2025
- Start date
- 2 Mar 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- American University
- Diseases
- Migraine
- NCT number
- NCT07360405
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 2 Mar 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of medications affecting glutamatergic or gamma-Aminobutyric Acid (GABA) neurotransmission (unless discontinued under physician guidance)
- Current use of quarterly injectable migraine preventive medications
Other illness
- Substance use disorder within the past year
- Diagnosed seizure disorder
Other
- Current pregnancy, plans to become pregnant during the study timeframe, or current breastfeeding
- Unwillingness to modify dietary intake or to stop alcohol and marijuana use during the study
- Severe asthma requiring past hospitalization
Who the study is looking for
- Men and women of all races and ethnicities
- Age 18-75 years
- Documented diagnosis of chronic or episodic migraine for at least 6 months, based on International Classification of Headache Disorders, 3rd edition (ICHD-III) criteria, defined as:
- 8 headache days per month, and
- 4 migraine days per month
- Migraine onset before age 50
- On a stable medication regimen for at least 1 month prior to enrollment
- Willing to maintain stable medications throughout the study
- Willing to discontinue supplements during the study period
- Women of childbearing potential must be willing to use birth control during the study timeframe
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| American University Coordinator of this site? Confirm its status | Washington D.C. | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.